Updates

Ergomed

May 2021

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

The expectation for FY20 had been £14.2m EBITDA, but as the year progressed this increased to £18.2m but Ergomed trumped even this and delivered £19.4m. Adjusted eps were up 29% to 24.7p. There’s been some pretty faultless execution during a pandemic by Richard Barfield, who I met again during the month. In the past 18 months, the scale of the business has been transformed with £12m spent on two bolt-ons to establish a foothold in the US, the largest clinical trials market in the world (>50% of clinical trials are run there) with Ashfield PV bought in January and US-based CRO Medsource in December, a 20 year-old business working on 200 oncology trials. US headcount ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Strix - Strategy to double sales by 2025

Various Eateries - Homeworking takes root - one to watch

Ergomed - Permira bids 1350p (September 2023)

Ergomed - 80%+ of this year’s forecast covered (September 2022)

Ergomed - Well set for an eps ‘beat’ (August 2022)

Ergomed (April 2022)

Ergomed - Buys specialist consultancy for £25.6m (March 2022)

Ergomed (October 2021)

Ergomed (January 2021)

Ergomed - "Hidden order bank" (October 2020)

Ergomed - Another big "beat" (August 2020)

Ergomed - Forecasts lifted again - by 5% (July 2020)

Ergomed - COVID-19 trial work underway (April 2020)

Ergomed - Earnings accretive deal (February 2020)

Ergomed - Taking a share in a winning streak (October 2019)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X